Bio Path reported $690K in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Baxter International USD 20.06B 1.01B Dec/2025
Bio Path USD 690K 56K Sep/2025
Cipla INR 401.64B 27.77B Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025